Results 1 to 10 of about 778,157 (293)

Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication

Viruses, 2022
The COVID-19 pandemic continues to threaten healthcare systems worldwide due to the limited access to vaccines, suboptimal treatment options, and the continuous emergence of new and more transmissible SARS-CoV-2 variants.
Ulrik Fahnøe, Long V. Pham, Carlota Fernandez-Antunez, Rui Costa, Lizandro René Rivera-Rangel, Andrea Galli, Shan Feng, Lotte S. Mikkelsen, Judith M. Gottwein, Troels K. H. Scheel, Santseharay Ramirez, Jens Bukh   +11 more
doaj   +1 more source

Lipid Droplets Accumulation during Hepatitis C Virus Infection in Cell-Culture Varies among Genotype 1–3 Strains and Does Not Correlate with Virus Replication

Viruses, 2021
Liver steatosis is a common complication of chronic hepatitis C virus (HCV) infection, which can result in accelerated liver fibrosis development, especially in patients infected with genotype 3a.
Andrea Galli, Santseharay Ramirez, Jens Bukh   +2 more
doaj   +1 more source

Alinity m, a Random-Access System, for Hepatitis B Virus DNA Quantification in Plasma and Whole Blood Collected on Dried Blood Spots

mSphere, 2022
The International Liver Association recommends the use of accurate and sensitive molecular methods for determination of hepatitis B virus (HBV) DNA levels in plasma or serum of chronic HBsAg carriers. The level of HBV replication represents the strongest
Valérie Ortonne, Quentin Lucas, Olivia Garrigou, Alexandre Soulier, Dominique Challine, Jean-Michel Pawlotsky, Vincent Leroy, Stéphane Chevaliez   +7 more
doaj   +1 more source

Association of PNPLA3 rs738409 G/C gene polymorphism with nonalcoholic fatty liver disease in children: a meta-analysis

BMC Medical Genetics, 2020
Background Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide. Current studies have shown that PNPLA3 (Patatin-like phospholipase domain containing 3) rs738409 G/C gene polymorphism is associated ...
Shan Tang, Jing Zhang, Ting Ting Mei, Hai Qing Guo, Xin Huan Wei, Wen Yan Zhang, Ya Li Liu, Shan Liang, Zuo Peng Fan, Li Xia Ma, Wei Lin, Yi Rong Liu, Li Xia Qiu, Hai Bin Yu   +13 more
doaj   +1 more source

In vitro efficacy of artemisinin-based treatments against SARS-CoV-2

Scientific Reports, 2021
Effective and affordable treatments for patients suffering from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are needed.
Yuyong Zhou, Kerry Gilmore, Santseharay Ramirez, Eva Settels, Karen A. Gammeltoft, Long V. Pham, Ulrik Fahnøe, Shan Feng, Anna Offersgaard, Jakob Trimpert, Jens Bukh, Klaus Osterrieder, Judith M. Gottwein, Peter H. Seeberger   +13 more
doaj   +1 more source

SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor

Vaccines, 2021
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has demonstrated the value of pursuing different vaccine strategies. Vaccines based on whole viruses, a widely used vaccine technology, depend on efficient virus production.
Anna Offersgaard, Carlos Rene Duarte Hernandez, Anne Finne Pihl, Rui Costa, Nandini Prabhakar Venkatesan, Xiangliang Lin, Long Van Pham, Shan Feng, Ulrik Fahnøe, Troels Kasper Høyer Scheel, Santseharay Ramirez, Udo Reichl, Jens Bukh, Yvonne Genzel, Judith Margarete Gottwein   +14 more
doaj   +1 more source

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir

Viruses, 2023
Nirmatrelvir, which targets the SARS-CoV-2 main protease (Mpro), is the first-in-line drug for prevention and treatment of severe COVID-19, and additional Mpro inhibitors are in development.
Karen Anbro Gammeltoft, Yuyong Zhou, Line Abildgaard Ryberg, Long V. Pham, Alekxander Binderup, Carlos Rene Duarte Hernandez, Anna Offersgaard, Ulrik Fahnøe, Günther Herbert Johannes Peters, Santseharay Ramirez, Jens Bukh, Judith Margarete Gottwein   +11 more
doaj   +1 more source

Chronic hepatitis C elimination prison initiative: HCV‐intensive test and treat, a whole prisoner population HCV test‐and‐treat program in England

Health Science Reports, 2023
Background and Aim Prison residents are at high risk for hepatitis C virus (HCV) infection. HCV test‐and‐treat initiatives within prisons provide an opportunity to engage with prison residents and achieve HCV micro‐elimination.
Rachel Halford, Lee Christensen, Sean Cox, Julia Sheehan, Iain Brew, Mark Gillyon‐Powell, Georgia Threadgold, Éamonn O'Moore, Philip J. F. Troke, Andy Jones   +9 more
doaj   +1 more source

Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro

Viruses, 2021
We report the in vitro efficacy of ion-channel inhibitors amantadine, memantine and rimantadine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Yuyong Zhou, Karen A. Gammeltoft, Andrea Galli, Anna Offersgaard, Ulrik Fahnøe, Santseharay Ramirez, Jens Bukh, Judith M. Gottwein   +7 more
doaj   +1 more source

Identification of Novel Determinants of Neutralization Epitope Shielding for Hepatitis C Virus in Vitro

Proceedings, 2020
Epitope shielding is suggested as an important mechanism mediating the escape of hepatitis C virus (HCV) from host-neutralizing antibodies (nAb). [...]
Garazi Peña Alzua, Anne Finne Pihl, Anna Falden Offersgaard, Rodrigo Velázquez-Moctezuma, Elias Honeroed Augestad, Ulrik Fahnøe, Christian Kjaerulff Mathiesen, Mansun Law, Jannick Prentoe, Jens Bukh, Judith Margarete Gottwein   +10 more
doaj   +1 more source